1 - Title Slide 2 - Disclosures 3 - Outline 4 - Background and Scope 5 - Prevalence of HF 6 - Prevalence and Incidence Rates 7 - Cumulative Incidence Curves 8 - Five-Year Outcomes 9 - Age % Distribution by Sex 10 - AHFT & Transplant Volumes 11 - Age-Adjusted Mortality Rates 12 - Risk by Race and Ethnicity 13 - 1/2 HF patients die within 5 yrs 14 - Projected Mortality 15 - Median Survival Decreases 16 - Projected Increased Costs 17 - Impact of Heart Failure 18 - AHFT: Who? 19 - Classification of HF 20 - NYHA Classification of HF 1994 21 - ACC/AHA HF Staging 2005 22 - INTERMACS- 2006 23 - Risk Stratification 24 - 2022 AHA/ACC/HFSA Guidelines 25 - Intolerance of ACE… 26 - Survival by number of risk factors 27 - Heart Failure Survival Score 28 - VO2-oxygen Consumption Risk 29 - Seattle Heart Failure Score 30 - Seattle HF Score (cont.) 31 - CPET Predictors 32 - Survival with 6MWT 33 - Mortality and 6MWT 34 - Under Utilized 6 MWT 35 - 6 MWT Prognostication 36 - Survival without Transplant 37 - ADHERE Mortality Rates 38 - Hosp., Renal failure and Survival 39 - Diuretic Dose 40 - Survival and ICD Shock 41 - Outpatient Inotropic Support 42 - Symptom improvement 43 - Guidelines for Referral of AHFT 44 - Warning Signs? 45 - AHFT: When 46 - NYHA Class III into Class IV 47 - Survival Post 48 - Timing of Advanced Therapies 49 - Timing of AT (cont.) 50 - Referral of Patients with AHF 51 - Early Referral 52 - Time to Think 53 - Shared Care Model 54 - Likelihood to Accept MCS 55 - Early Shared Decision Making 56 - AHFT: What 57 - Management of Patients 58 - Assessment for AT 59 - Heart Transplant -1967 Barnard 60 - Adult Heart Transplants 61 - Let’s Do The Math 62 - Can VADs help? 63 - STS-Intermacs 2020 AR 64 - Improved Survival 65 - Heart Mate 3 66 - Event-free Survival 67 - Event-free Survival (cont.) 68 - Reversed Heart Failure Symptoms 69 - Patient Quality Of Life 70 - Reduction In Rehospitalizations 71 - Evolving Technology 72 - Heart Failure Community 73 - Underpenetrated VAD Therapy 74 - VAD Therapy (cont.) 75 - Candidates for LVAD 76 - In Conclusion…. 77 - Thank You!